Frankfurt - Delayed Quote EUR

Moberg Pharma AB (publ) (MB8.F)

0.6740

-0.0105

(-1.53%)

At close: April 25 at 8:06:40 AM GMT+2

Terclara (MOB-015) is now being launched in Norway

Moberg Pharma AB (OMX: MOB) and Allderma today announce that the launch of Terclara® (MOB-015) is ongoing in Norway. The launch marks an important step in both companies' commercial strategy and builds on the successful launch in Sweden, where Terclara® is the market leader.

PR Newswire 2 months ago

MBGPF
Moberg Pharma reports topline data in the North American phase 3 study and will regain rights to MOB-015 in EU

Moberg Pharma AB (OMX: MOB) announces that MOB-015 (topical terbinafine) did not meet the primary endpoint in the phase 3 study using 8 weeks of daily dosing followed by weekly maintenance dosing. The company's focus going forward will be on the effective daily dosing regimen approved in 13 EU countries.

PR Newswire 4 months ago

MBGPF
Cipher Pharmaceuticals Down 16% as Partner Moberg Pharma AB Provides Lower Than Expected Study Results

Cipher Pharmaceuticals Down 16% as Partner Moberg Pharma AB Provides Lower Than Expected Study Results

PREMIUM
MT Newswires 7 months ago

MOB.ST
+2.47%
CPHRF
Moberg Pharma lowers expectations on primary endpoint in ongoing phase 3 trial following data in a subset of patients

Moberg Pharma AB (OMX: MOB) announces that the company has received information about clinical cure in a subset of patients in the ongoing North American Phase 3 study for MOB-015 against nail fungus. The number of patients who have achieved clinical cure in this blinded subset of patients is lower than the company's expectations, which necessitates that Moberg Pharma inform the market about this fact.

PR Newswire 7 months ago

MBGPF
Moberg Pharma receives SEK 336 million through TO 2 and directed issue to top guarantors - subscription rate in TO 2 of 98%

("Moberg Pharma" or the "Company") announces that 17,776,856 warrants of series 2023:1 ("TO 2") were exercised for subscription of in total 17,776,856 ordinary shares for approximately SEK 320 million, corresponding to a subscription rate of approximately 98%. As announced by the Company on June 11th, 2024, subscription and top guarantee commitments had been made for TO 2, free of charge, with certain external professional investors, and today the board of directors has resolved on a directed is

PR Newswire 9 months ago

MBGPF
Moberg Pharma has secured exercise of warrants and entered into a top guarantee free of charge

Moberg Pharma AB (publ) ("Moberg Pharma" or the "Company") has today received subscription intentions, subscription commitments and top guarantee commitments totaling approximately SEK 113.5 million, related to the warrants of series 2023:1 ("TO 2"), from a few external professional investors and the Company's largest shareholder, Östersjöstiftelsen (The Baltic Sea Foundation).

PR Newswire 10 months ago

MBGPF

Performance Overview

Return	MB8.F	OMX Stockholm 30 Index (^OMX)
YTD	-19.71%	-2.26%
1-Year	-76.61%	-3.90%
3-Year	-54.54%	+18.35%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Moberg Pharma AB (publ) (MB8.F)

Terclara (MOB-015) is now being launched in Norway

Moberg Pharma reports topline data in the North American phase 3 study and will regain rights to MOB-015 in EU

Cipher Pharmaceuticals Down 16% as Partner Moberg Pharma AB Provides Lower Than Expected Study Results

Moberg Pharma lowers expectations on primary endpoint in ongoing phase 3 trial following data in a subset of patients

Moberg Pharma receives SEK 336 million through TO 2 and directed issue to top guarantors - subscription rate in TO 2 of 98%

Moberg Pharma has secured exercise of warrants and entered into a top guarantee free of charge

Performance Overview